Metadate Related Published Studies
Well-designed clinical trials related to Metadate (Methylphenidate)
The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1
Trial. [2015]
Drug-specific laterality effects on frontal lobe activation of atomoxetine and
methylphenidate in attention deficit hyperactivity disorder boys during working
memory. [2014]
Long-term (1 year) safety and efficacy of methylphenidate modified-release
long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity
disorder: a 26-week, flexible-dose, open-label extension to a 40-week,
double-blind, randomised, placebo-controlled core study. [2014]
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on
sleep: a double-blind, randomized, crossover study in youth with
attention-deficit hyperactivity disorder. [2014]
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate
the efficacy and safety of osmotic-controlled release oral delivery system
methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in
Japan. [2014]
Effect of methylphenidate and folic Acid on ADHD symptoms and quality of life and
aggression: a randomized double blind placebo controlled clinical trial. [2013]
Effects of methylphenidate on acute math performance in children with
attention-deficit hyperactivity disorder. [2013]
Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of
attention, behavior, and performance benefits in children with
attention-deficit/hyperactivity disorder. [2013]
A post hoc comparison of the effects of lisdexamfetamine dimesylate and
osmotic-release oral system methylphenidate on symptoms of attention-deficit
hyperactivity disorder in children and adolescents. [2013]
NWP06, an extended-release oral suspension of methylphenidate, improved
attention-deficit/hyperactivity disorder symptoms compared with placebo in a
laboratory classroom study. [2013]
Randomized controlled double-blind trial of optimal dose methylphenidate in
children and adolescents with severe attention deficit hyperactivity disorder and
intellectual disability. [2013]
Ameliorating attention problems in children with sickle cell disease: a pilot
study of methylphenidate. [2012]
Methylphenidate treatment of adult male prison inmates with attention-deficit
hyperactivity disorder: randomised double-blind placebo-controlled trial with
open-label extension. [2012]
Is response to OROS-methylphenidate treatment moderated by treatment with
antidepressants or psychiatric comorbidity? A secondary analysis from a large
randomized double blind study of adults with ADHD. [2012]
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. [2011.11.04]
Comparison of the Efficacy of Two Different Modified Release Methylphenidate Preparations for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a Natural Setting: Comparison of the Efficacy of Medikinet((R)) Retard and Concerta((R))-a Randomized, Controlled, Double-Blind Multicenter Clinical Crossover Trial. [2011.10]
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. [2011.09]
Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder. [2011.09]
Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. [2011.07]
Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. [2011.06]
Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. [2011.06]
Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. [2011.05.01]
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. [2011.04.05]
Academic, behavioral, and cognitive effects of OROS(R) methylphenidate on older children with attention-deficit/hyperactivity disorder. [2011.04]
Effects of OROS methylphenidate on academic, behavioral, and cognitive tasks in children 9 to 12 years of age with attention-deficit/hyperactivity disorder. [2011.04]
Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke--a randomized, double-blind, placebo-controlled trial. [2011.04]
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. [2011.02.01]
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. [2011.02]
Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial. [2011.01.28]
Methylphenidate increases choice of cigarettes over money. [2011.01]
Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. [2011]
Dose effects and comparative effectiveness of extended release dexmethylphenidate
and mixed amphetamine salts. [2011]
Gender differences in the effects of methylphenidate on energy intake in young
adults: a preliminary study. [2011]
An exploration of site effects in a multisite trial of OROS-methylphenidate for
smokers with attention deficit/hyperactivity disorder. [2011]
Methylphenidate normalizes frontocingulate underactivation during error
processing in attention-deficit/hyperactivity disorder. [2011]
Effect of osmotic-release oral system methylphenidate on different domains of
attention and executive functioning in children with
attention-deficit-hyperactivity disorder. [2011]
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical
trial. [2011]
Effects of OROS methylphenidate on academic, behavioral, and cognitive tasks in
children 9 to 12 years of age with attention-deficit/hyperactivity disorder. [2011]
Long-term safety of OROS methylphenidate in adults with
attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year
study. [2011]
Methylphenidate transdermal system in adult ADHD and impact on emotional and
oppositional symptoms. [2011]
A one year trial of methylphenidate in the treatment of ADHD. [2011]
Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. [2010.12.14]
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. [2010.12.08]
Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. [2010.12]
Methylphenidate for fatigue in ambulatory men with prostate cancer. [2010.11.01]
A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin((R)) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks. [2010.11]
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. [2010.11]
Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. [2010.11]
A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. [2010.10]
Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. [2010.10]
Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. [2010.10]
Methylphenidate significantly improves declarative memory functioning of adults with ADHD. [2010.10]
The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. [2010.09]
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. [2010.08.10]
OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. [2010.08]
Testing Tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. [2010.08]
Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. [2010.07.09]
OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. [2010.07.01]
Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. [2010.07]
Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. [2010.07]
Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke - a randomized, double-blind, placebo-controlled trial. [2010.06.21]
Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. [2010.06]
Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder. [2010.06]
A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. [2010.05]
Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. [2010.05]
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. [2010.04.01]
Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial. [2010.03]
A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. [2010.02]
A One Year Trial of Methylphenidate in the Treatment of ADHD. [2010.01.13]
A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of
osmotic-release oral system-methylphenidate in adults with
attention-deficit/hyperactivity disorder. [2010]
Phase III, randomized, double-blind, placebo-controlled study of long-acting
methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group
NCCTG-N05C7 trial. [2010]
Buspirone versus methylphenidate in the treatment of attention deficit
hyperactivity disorder: a double-blind and randomized trial. [2010]
Adaptive phase I study of OROS methylphenidate treatment of attention deficit
hyperactivity disorder with epilepsy. [2010]
Clinical response to methylphenidate in children diagnosed with attention-deficit
hyperactivity disorder and comorbid psychiatric disorders. [2010]
Personality disorders in ADHD Part 2: The effect of symptoms of personality
disorder on response to treatment with OROS methylphenidate in adults with ADHD. [2010]
Personality disorder in ADHD Part 1: Assessment of personality disorder in adult
ADHD using data from a clinical trial of OROS methylphenidate. [2010]
Methylphenidate enhances prepulse inhibition during processing of task-relevant
stimuli in attention-deficit/hyperactivity disorder. [2010]
Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. [2009.12]
HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. [2009.12]
Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. [2009.12]
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. [2009.11]
Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. [2009.10]
Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. [2009.10]
Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. [2009.10]
Stimulant treatment reduces lapses in attention among children with ADHD: the effects of methylphenidate on intra-individual response time distributions. [2009.08]
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. [2009.08]
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. [2009.08]
Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. [2009.07]
Behavioral response to methylphenidate challenge: influence of early life parental care. [2009.07]
Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. [2009.06]
Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. [2009.06]
Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. [2009.06]
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. [2009.06]
Predicting Methylphenidate Response in Long-Term Survivors of Childhood Cancer: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. [2009.05.22]
The effect of methylphenidate on postural stability under single and dual task conditions in children with attention deficit hyperactivity disorder - a double blind randomized control trial. [2009.05.15]
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. [2009.05]
Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). [2009.05]
Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial. [2009.05]
Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. [2009.04.01]
Methylphenidate restores link between stop-signal sensory impact and successful stopping in adults with attention-deficit/hyperactivity disorder. [2009.04.01]
Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. [2009.04]
|
